BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Bristol Myers Squibb names Singapore as new Pan Asia Hub

July 8, 2026 | News

Company reinforces its commitment to Singapore to advance the local life sciences ecosystem



Bristol Myers Squibb (BMS), a global biopharmaceutical leader, recently celebrated its 60th anniversary in Singapore by recognising it as a new Pan Asia Cluster (PAC) hub for the company.

Supported by the Singapore Economic Development Board (EDB), the hub will accelerate patient access and innovation in the region and see the addition of key talent based in Singapore.

The hub, which currently employs over 200 employees, brings together markets including Hong Kong & Macau, Taiwan, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines.

The hub will strengthen capabilities and talent at scale, strategically leveraging partnerships and delivering enhanced patient impact.

Currently, American pharma firm BMS has more than 60 clinical trials in the PAC region, with five new trials targeted to start in Singapore by end of 2026.